Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06548360 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
A Phase 3 study of Non-segmental Vitiligo, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06548360: Recruiting Phase 3 study of Non-segmental Vitiligo, sponsored by Incyte Corporation.
NCT06548360 is a Phase 3 study of Non-segmental Vitiligo that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 180 participants, below the 250-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06548360, a Phase 3 study of Non-segmental Vitiligo, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Primary Outcome
≥75% improvement in facial Vitiligo Area Scoring Index.
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream
- DRUG Vehicle Cream
Study Locations (20)
California
- Axon Clinical Research - Inglewood
- University of California Irvine - Irvine
- Vitiligo & Pigmentation Institute of Southern California - Los Angeles
- Dermatology Research Associates - Los Angeles
- La Universal Research Center, Inc - Los Angeles
- Stanford School of Medicine - Palo Alto
- Empire Clinical Research - Pomona
- Norcal Clinical Research - Rocklin
- Peninsula Research Associates Pra - Rolling Hills Estates
- Integrative Skin Science and Research - Sacramento
- Rady Children'S Hospital-San Diego - San Diego
Arizona
- Phoenix Children'S Hospital - Phoenix
- Omni Dermatology - Phoenix
- Affiliated Dermatology - Scottsdale
- Banner - University Medicine Multispecialty Services Clinic - Tucson
Arkansas
- Premier Dermatology Clinical Trials Institute At Northwest Arkansas - Fayetteville
- Burke Pharmaceutical Research - Hot Springs
Colorado
- Children'S Hospital Colorado - Aurora
- Paradigm Clinical Research Centers, Inc. - Wheat Ridge
Alabama
- University of Alabama At Birmingham-School of Medicine - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2027-03-13 |
| Phase | Phase 3 |
What NCT06548360 shows while recruiting
NCT06548360 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 250-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib Cream is the first listed.
NCT06548360 names 20 study sites across 5 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06548360 about?
NCT06548360 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo". The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
What is the current status of trial NCT06548360?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-01-24. Estimated completion is 2027-03-13.
What conditions does trial NCT06548360 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT06548360?
The interventions under investigation include: Ruxolitinib Cream (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT06548360?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06548360 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06548360's enrollment target sits among peer trials
180 8th of 9 higher than 2 of 9 other Non-segmental Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-segmental Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
ACTIVE NOT RECRUITING · Phase 3
-
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
COMPLETED · Phase 3
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI